Palatin Technologies

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. The company is headquartered in Cranbury, New Jersey and currently employs 29 full-time employees. The firm is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. The MCR system has effects on inflammation and immune system response, food intake, metabolism, and sexual function. Its product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. Its product development activities focus primarily on the use of MC4R agonists for treatment of obesity. The company develops MC4R peptides and small molecule agonists with potential utility in obesity and metabolic-related disorders, rare MC4R pathway diseases, such as hypothalamic obesity, and orphan indications. The company also develops MC1R agonist products to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease.